Near doubling of survival at 1 and 2 years in pretreated patients1
Read more about second-line treatment
A consistent efficacy in first-line patients1
Read more about first-line treatment
Novel Mechanism of Action
In contrast to cytotoxic chemotherapy drugs, YERVOY™ works by activating the patient’s own immune system to destroy melanoma tumours. (1,4)
Specific patterns of response
As it can take some time to prime the immunesystem to fight the tumour, it is not surprising that many advanced (unresectable or metastatic) melanoma patients display atypical, delayed responses to YERVOY™. (4)
1. YERVOY™ Summary of Product Characteristics.
2. Eggermont AM. Advances in systemic treatment of melanoma. Ann Oncol. 2010;21 Suppl 7:vii339-vii344.
3. European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) Assessment Report For YERVOY® (ipilimumab)
24 October 2013.
4. Hoos A et al. J Natl Cancer Inst. 2010 Sep 22;102(18):1388-1397.